Examining Association Between Early Treatment With Tocilizumab, Risk of Death Among Critically Ill COVID-19 Patients

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 1 P.M. (ET), TUESDAY, OCTOBER 20, 2020

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.6252?guestAccessKey=8a81e35e-df54-4c43-8729-d5d28e48b666&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102020

 

What The Study Did: Whether treatment with tocilizumab in the first two days after being admitted to an intensive care unit was associated with a reduced risk of death among critically ill patients with COVID-19 was investigated in this study.

Authors: David E. Leaf, M.D., M.M.Sc., of Brigham and Women’s Hospital in Boston, is the corresponding author.

 

(doi:10.1001/jamainternmed.2020.6252)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.